

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICATION NO.:	10/541,708	ATTY. DOCKET NO.:	A0848.70010US00
		FILING DATE:	July 8, 2005	CONFIRMATION NO.:	6032
		APPLICANT:	Karen Silence		
		GROUP ART UNIT:	1644	EXAMINER:	M. E. Szperka
Sheet	1	of	1		

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

OTHER ART - NON-PATENT LITERATURE DOCUMENTS			
Examiner's Initials [#]	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		OHNO et al., Antigen-binding specificities of antibodies are primarily determined by seven residues of VH. Proc Natl Acad Sci U S A. 1985 May;82(9):2945-9.	

EXAMINER: DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR § 1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR § 1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR § 1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. § 120.]